{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:59:52Z","timestamp":1781632792103,"version":"3.54.5"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005378","name":"Hacettepe University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005378","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Kawasaki Disease (KD) is a medium vessel vasculitis of young children that affects coronary arteries (CAs). The aim of therapy is to control inflammation and prevent coronary artery damage and alleviate thrombosis. This review aims to summarize the thrombosis-related complications and complementary therapy approaches to combat them. It also focuses on the ambiguity regarding the optimal aspirin dose in standard KD therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>KD patients with large or giant coronary artery aneurysms (CAAs) in particular face the risk of developing thrombosis. The standard therapy regimen during the acute phase consists of intravenous immunoglobulin (IVIG) plus aspirin. Although the dosing for IVIG is constant, the aspirin dose continues to be debated. The standard treatment with aspirin and IVIG might be adequate for individuals with small aneurysms whereas, patients suffering from large aneurysms and in a hypercoagulable state might need additional and extended therapy consisting of several antiplatelet reagents and anticoagulants. In case of thrombosis formation, thrombolytic therapy is also recommended.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Cardiac and thrombotic problems are severe outcomes of KD. Patients need to be screened on a regular basis with echocardiography. The ideal aspirin dose during acute KD treatment is still controversial and while several recent studies pinpoint the superiority of low doses, there is no universal consensus. The variation in treatment response might be due to the different ethnic composition of study groups and inter-individual differences. Overall, close monitoring of patient response and finding the optimal treatment strategy is crucial.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11926-026-01211-5","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T09:33:43Z","timestamp":1770370423000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Thrombo-inflammation and Rethinking the Role of Aspirin in Kawasaki Disease"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3657-6055","authenticated-orcid":false,"given":"Beg\u00fcm","family":"Kocat\u00fcrk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7189-6214","authenticated-orcid":false,"given":"Beyda","family":"Berbero\u011fullar\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3574-2982","authenticated-orcid":false,"given":"Emil","family":"Aliyev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6542-2656","authenticated-orcid":false,"given":"Erdal","family":"Sa\u011f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2883-7868","authenticated-orcid":false,"given":"Seza","family":"\u00d6zen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9042-2909","authenticated-orcid":false,"given":"Moshe","family":"Arditi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"1211_CR1","doi-asserted-by":"publisher","first-page":"e927","DOI":"10.1161\/CIR.0000000000000484","volume":"135","author":"BW McCrindle","year":"2017","unstructured":"McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135:e927\u201399.","journal-title":"Circulation"},{"key":"1211_CR2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jpeds.2016.12.019","volume":"184","author":"GB Kim","year":"2017","unstructured":"Kim GB, Yu JJ, Yoon KL, Jeong SI, Song YH, Han JW, et al. Medium- or higher-dose acetylsalicylic acid for acute kawasaki disease and patient outcomes. J Pediatr. 2017;184:125\u20139.","journal-title":"J Pediatr"},{"key":"1211_CR3","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/j.carrev.2018.11.021","volume":"20","author":"SK Agarwal","year":"2019","unstructured":"Agarwal SK, Agarwal S. Role of intracoronary fibrinolytic therapy in contemporary PCI practice. Cardiovasc Revasc Med. 2019;20:1165\u201371.","journal-title":"Cardiovasc Revasc Med"},{"key":"1211_CR4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/QCO.0b013e3282fbf9cd","volume":"21","author":"GS Pinna","year":"2008","unstructured":"Pinna GS, Kafetzis DA, Tselkas OI, Skevaki CL. Kawasaki disease: an overview. Curr Opin Infect Dis. 2008;21:263\u201370.","journal-title":"Curr Opin Infect Dis"},{"key":"1211_CR5","doi-asserted-by":"publisher","first-page":"e1284","DOI":"10.1002\/cti2.1284","volume":"10","author":"T Hara","year":"2021","unstructured":"Hara T, Yamamura K, Sakai Y. The up-to-date pathophysiology of Kawasaki disease. Clin Transl Immunol. 2021;10:e1284.","journal-title":"Clin Transl Immunol"},{"key":"1211_CR6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3389\/fped.2019.00018","volume":"7","author":"S Nagata","year":"2019","unstructured":"Nagata S. Causes of Kawasaki disease-from past to present. Front Pediatr. 2019;7:18.","journal-title":"Front Pediatr"},{"key":"1211_CR7","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s10067-020-05328-5","volume":"40","author":"AZ Banday","year":"2021","unstructured":"Banday AZ, Bhattacharya D, Pandiarajan V, Singh S. Kawasaki disease in siblings in close temporal proximity to each other-what are the implications? Clin Rheumatol. 2021;40:849\u201355.","journal-title":"Clin Rheumatol"},{"key":"1211_CR8","doi-asserted-by":"publisher","first-page":"e481","DOI":"10.1161\/CIR.0000000000001295","volume":"150","author":"PN Jone","year":"2024","unstructured":"Jone PN, Tremoulet A, Choueiter N, Dominguez SR, Harahsheh AS, Mitani Y, et al. Update on diagnosis and management of Kawasaki disease: a scientific statement from the American Heart Association. Circulation. 2024;150:e481\u2013500.","journal-title":"Circulation"},{"key":"1211_CR9","first-page":"2747","volume":"110","author":"JW Newburger","year":"2004","unstructured":"Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young. American Heart Association Circulation. 2004;110:2747\u201371.","journal-title":"American Heart Association Circulation"},{"key":"1211_CR10","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1080\/1744666X.2019.1659726","volume":"15","author":"AK Jindal","year":"2019","unstructured":"Jindal AK, Pilania RK, Prithvi A, Guleria S, Singh S. Kawasaki disease: characteristics, diagnosis, and unusual presentations. Expert Rev Clin Immunol. 2019;15:1089\u2013104.","journal-title":"Expert Rev Clin Immunol"},{"key":"1211_CR11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jpeds.2007.12.021","volume":"153","author":"AH Tremoulet","year":"2008","unstructured":"Tremoulet AH, Best BM, Song S, Wang S, Corinaldesi E, Eichenfield JR, et al. Resistance to intravenous immunoglobulin in children with Kawasaki disease. J Pediatr. 2008;153:117\u201321.","journal-title":"J Pediatr"},{"key":"1211_CR12","doi-asserted-by":"crossref","unstructured":"Pilania RK, Tremoulet AH, Prinja S, Dahdah N, Singh S. Kawasaki disease: the most common cause of acquired heart disease among children globally. Cardiol Young. 2025;1\u20133.","DOI":"10.1017\/S1047951125000459"},{"key":"1211_CR13","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1161\/01.CIR.94.6.1379","volume":"94","author":"H Kato","year":"1996","unstructured":"Kato H, Sugimura T, Akagi T, Sato N, Hashino K, Maeno Y, et al. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation. 1996;94:1379\u201385.","journal-title":"Circulation"},{"key":"1211_CR14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.bj.2017.04.002","volume":"40","author":"HC Kuo","year":"2017","unstructured":"Kuo HC. Preventing coronary artery lesions in Kawasaki disease. Biomed J. 2017;40:141\u20136.","journal-title":"Biomed J"},{"key":"1211_CR15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/0090-1229(88)90088-8","volume":"48","author":"S Furukawa","year":"1988","unstructured":"Furukawa S, Matsubara T, Jujoh K, Yone K, Sugawara T, Sasai K, et al. Peripheral blood monocyte\/macrophages and serum tumor necrosis factor in Kawasaki disease. Clin Immunol Immunopathol. 1988;48:247\u201351.","journal-title":"Clin Immunol Immunopathol"},{"key":"1211_CR16","doi-asserted-by":"crossref","unstructured":"Visi G, Spina F, Del DF, Manetti AC, Maiese A, La RRet al. Autoptic Findings in cases of sudden death due to Kawasaki Disease. Diagnostics (Basel). 2023;13.","DOI":"10.3390\/diagnostics13111831"},{"key":"1211_CR17","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1161\/01.CIR.89.1.258","volume":"89","author":"T Sugimura","year":"1994","unstructured":"Sugimura T, Kato H, Inoue O, Fukuda T, Sato N, Ishii M, et al. Intravascular ultrasound of coronary arteries in children. Assessment of the wall morphology and the lumen after Kawasaki disease. Circulation. 1994;89:258\u201365.","journal-title":"Circulation"},{"issue":"3","key":"1211_CR18","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1136\/heart.83.3.307","volume":"83","author":"M Iemura","year":"2000","unstructured":"Iemura M, Ishii M, Sugimura T, Akagi T, Kato H. Long term consequences of regressed coronary aneurysms after Kawasaki disease: vascular wall morphology and function. Heart. 2000;83(3):307\u201311.","journal-title":"Heart"},{"key":"1211_CR19","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1055\/s-0037-1615022","volume":"79","author":"A Ishiguro","year":"1998","unstructured":"Ishiguro A, Ishikita T, Shimbo T, Matsubara K, Baba K, Hayashi Y, et al. Elevation of serum thrombopoietin precedes thrombocytosis in Kawasaki disease. Thromb Haemost. 1998;79:1096\u2013100.","journal-title":"Thromb Haemost"},{"key":"1211_CR20","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.169855","author":"B Kocaturk","year":"2023","unstructured":"Kocaturk B, Lee Y, Nosaka N, Abe M, Martinon D, Lane ME, et al. Platelets exacerbate cardiovascular inflammation in a murine model of Kawasaki disease vasculitis. JCI Insight. 2023;8","journal-title":"JCI Insight"},{"key":"1211_CR21","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1136\/bmj.290.6480.1456","volume":"290","author":"M Levin","year":"1985","unstructured":"Levin M, Holland PC, Nokes TJ, Novelli V, Mola M, Levinsky RJ, et al. Platelet immune complex interaction in pathogenesis of Kawasaki disease and childhood polyarteritis. Br Med J (Clin Res Ed). 1985;290:1456\u201360.","journal-title":"Br Med J (Clin Res Ed)"},{"key":"1211_CR22","doi-asserted-by":"publisher","first-page":"17641","DOI":"10.1038\/s41598-019-54113-1","volume":"9","author":"X Zheng","year":"2019","unstructured":"Zheng X, Wu W, Zhang Y, Wu G. Changes in and significance of platelet function and parameters in Kawasaki disease. Sci Rep. 2019;9:17641.","journal-title":"Sci Rep"},{"key":"1211_CR23","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1007\/s00246-015-1138-0","volume":"36","author":"M Wei","year":"2015","unstructured":"Wei M, Huang M, Chen S, Huang G, Huang M, Qiu D, et al. A multicenter study of intravenous immunoglobulin non-response in Kawasaki disease. Pediatr Cardiol. 2015;36:1166\u201372.","journal-title":"Pediatr Cardiol"},{"key":"1211_CR24","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12969-021-00589-z","volume":"19","author":"X Zhang","year":"2021","unstructured":"Zhang X, He Y, Shao Y, Hang B, Xu Z, Chu M. Factors affecting the duration of coronary artery lesions in patients with the Kawasaki disease: a retrospective cohort study. Pediatr Rheumatol Online J. 2021;19:96.","journal-title":"Pediatr Rheumatol Online J"},{"key":"1211_CR25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/BF00442611","volume":"147","author":"T Hara","year":"1988","unstructured":"Hara T, Mizuno Y, Akeda H, Fukushige J, Ueda K, Aoki T, et al. Thrombocytopenia: a complication of Kawasaki disease. Eur J Pediatr. 1988;147:51\u20133.","journal-title":"Eur J Pediatr"},{"key":"1211_CR26","first-page":"857","volume":"6","author":"K Niwa","year":"1995","unstructured":"Niwa K, Aotsuka H, Hamada H, Uchishiba M, Terai M, Niimi H. Thrombocytopenia: a risk factor for acute myocardial infarction during the acute phase of Kawasaki disease. Coron Artery Dis. 1995;6:857\u201364.","journal-title":"Coron Artery Dis"},{"key":"1211_CR27","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00296-009-0947-y","volume":"30","author":"S Singh","year":"2009","unstructured":"Singh S, Gupta D, Suri D, Kumar RM, Ahluwalia J, Das R, et al. Thrombocytopenia as a presenting feature of Kawasaki disease: a case series from North India. Rheumatol Int. 2009;30:245\u20138.","journal-title":"Rheumatol Int"},{"key":"1211_CR28","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3389\/fped.2019.00423","volume":"7","author":"P Jin","year":"2019","unstructured":"Jin P, Luo Y, Liu X, Xu J, Liu C. Kawasaki disease complicated with macrophage activation syndrome: case reports and literature review. Front Pediatr. 2019;7:423.","journal-title":"Front Pediatr"},{"key":"1211_CR29","unstructured":"Noval RM, Kocaturk B, Franklin BS, Arditi M. Platelets in Kawasaki disease: mediators of vascular inflammation. Nat Rev Rheumatol. 2024."},{"key":"1211_CR30","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/S0022-3476(84)80114-6","volume":"105","author":"JC Burns","year":"1984","unstructured":"Burns JC, Glode MP, Clarke SH, Wiggins J Jr., Hathaway WE. Coagulopathy and platelet activation in Kawasaki syndrome: identification of patients at high risk for development of coronary artery aneurysms. J Pediatr. 1984;105:206\u201311.","journal-title":"J Pediatr"},{"key":"1211_CR31","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/j.1365-2141.2009.07922.x","volume":"148","author":"K Ueno","year":"2010","unstructured":"Ueno K, Nomura Y, Hashiguchi T, Masuda K, Morita Y, Hazeki D, et al. Platelet vascular endothelial growth factor is a useful predictor for prognosis in Kawasaki syndrome. Br J Haematol. 2010;148:285\u201392.","journal-title":"Br J Haematol"},{"key":"1211_CR32","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.thromres.2022.11.014","volume":"221","author":"Y Peng","year":"2023","unstructured":"Peng Y, Yi Q. Incidence and timing of coronary thrombosis in Kawasaki disease patients with giant coronary artery aneurysm. Thromb Res. 2023;221:30\u20134.","journal-title":"Thromb Res"},{"key":"1211_CR33","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jpeds.2015.04.036","volume":"167","author":"S Hoshino","year":"2015","unstructured":"Hoshino S, Tsuda E, Yamada O. Characteristics and fate of systemic artery aneurysm after Kawasaki disease. J Pediatr. 2015;167:108\u201312.","journal-title":"J Pediatr"},{"key":"1211_CR34","doi-asserted-by":"publisher","first-page":"1184162","DOI":"10.3389\/fimmu.2023.1184162","volume":"14","author":"J Liu","year":"2023","unstructured":"Liu J, Yuan P, Pang Y, Su D. ITPKC polymorphism (rs7251246 T > C), coronary artery aneurysms, and thrombosis in patients with Kawasaki disease in a Southern Han Chinese population. Front Immunol. 2023;14:1184162.","journal-title":"Front Immunol"},{"key":"1211_CR35","doi-asserted-by":"publisher","first-page":"e38998","DOI":"10.1371\/journal.pone.0038998","volume":"7","author":"JM Orenstein","year":"2012","unstructured":"Orenstein JM, Shulman ST, Fox LM, Baker SC, Takahashi M, Bhatti TR, et al. Three linked vasculopathic processes characterize Kawasaki disease: a light and transmission electron microscopic study. PLoS ONE. 2012;7:e38998.","journal-title":"PLoS ONE"},{"key":"1211_CR36","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/bjh.18531","volume":"200","author":"L Fu","year":"2023","unstructured":"Fu L, MacKeigan DT, Gong Q, Che D, Xu Y, Pi L, et al. Thymic stromal lymphopoietin induces platelet mitophagy and promotes thrombosis in Kawasaki disease. Br J Haematol. 2023;200:776\u201391.","journal-title":"Br J Haematol"},{"key":"1211_CR37","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/clinids\/14.1.121","volume":"14","author":"S Tomita","year":"1992","unstructured":"Tomita S, Chung K, Mas M, Gidding S, Shulman ST. Peripheral gangrene associated with Kawasaki disease. Clin Infect Dis. 1992;14:121\u20136.","journal-title":"Clin Infect Dis"},{"key":"1211_CR38","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1016\/j.jaad.2010.04.029","volume":"64","author":"E Gomez-Moyano","year":"2011","unstructured":"Gomez-Moyano E, Vera CA, Camacho J, Sanz TA, Crespo-Erchiga V. Kawasaki disease complicated by cutaneous vasculitis and peripheral gangrene. J Am Acad Dermatol. 2011;64:e74\u20135.","journal-title":"J Am Acad Dermatol"},{"key":"1211_CR39","doi-asserted-by":"publisher","first-page":"E70","DOI":"10.1532\/HSF98.20061151","volume":"10","author":"OF Dogan","year":"2007","unstructured":"Dogan OF, Kara A, Devrim I, Tezer H, Besbas N, Ozen S, et al. Peripheral gangrene associated with Kawasaki disease and successful management using prostacycline analogue: a case report. Heart Surg Forum. 2007;10:E70\u20132.","journal-title":"Heart Surg Forum"},{"key":"1211_CR40","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1007\/s00431-005-1699-7","volume":"164","author":"T Imamura","year":"2005","unstructured":"Imamura T, Yoshihara T, Yokoi K, Nakai N, Ishida H, Kasubuchi Y. Impact of increased D-dimer concentrations in Kawasaki disease. Eur J Pediatr. 2005;164:526\u20137.","journal-title":"Eur J Pediatr"},{"key":"1211_CR41","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12969-022-00738-y","volume":"20","author":"N Zhang","year":"2022","unstructured":"Zhang N, Yu L, Xiong Z, Hua Y, Duan H, Qiao L, et al. Kawasaki disease complicated by peripheral artery thrombosis: a case report and literature review. Pediatr Rheumatol Online J. 2022;20:77.","journal-title":"Pediatr Rheumatol Online J"},{"key":"1211_CR42","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1159\/000368402","volume":"165","author":"Y Sakurai","year":"2014","unstructured":"Sakurai Y, Takatsuka H, Onaka M, Takada M, Nishino M. Persistent endothelial damage after intravenous immunoglobulin therapy in Kawasaki disease. Int Arch Allergy Immunol. 2014;165:111\u20138.","journal-title":"Int Arch Allergy Immunol"},{"key":"1211_CR43","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1177\/000992289002900613","volume":"29","author":"JE Irazuzta","year":"1990","unstructured":"Irazuzta JE, Elbl F, Rees AR. Factor VIII related antigen (von Willebrand\u2019s factor) in Kawasaki disease. Clin Pediatr (Phila). 1990;29:347\u20138.","journal-title":"Clin Pediatr (Phila)"},{"key":"1211_CR44","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1086\/515133","volume":"28","author":"WH Mason","year":"1999","unstructured":"Mason WH, Takahashi M. Kawasaki syndrome. Clin Infect Dis. 1999;28:169\u201385.","journal-title":"Clin Infect Dis"},{"key":"1211_CR45","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/00001721-200302000-00010","volume":"14","author":"M Albisetti","year":"2003","unstructured":"Albisetti M, Chan AK, McCrindle BW, Wong D, Vegh P, Adams M, et al. Fibrinolytic response to venous occlusion is decreased in patients after Kawasaki disease. Blood Coagul Fibrinolysis. 2003;14:181\u20136.","journal-title":"Blood Coagul Fibrinolysis"},{"key":"1211_CR46","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jmii.2013.06.005","volume":"48","author":"PS Chen","year":"2015","unstructured":"Chen PS, Chi H, Huang FY, Peng CC, Chen MR, Chiu NC. Clinical manifestations of Kawasaki disease shock syndrome: a case-control study. J Microbiol Immunol Infect. 2015;48:43\u201350.","journal-title":"J Microbiol Immunol Infect"},{"key":"1211_CR47","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s12519-019-00234-6","volume":"15","author":"WX Kong","year":"2019","unstructured":"Kong WX, Ma FY, Fu SL, Wang W, Xie CH, Zhang YY, et al. Biomarkers of intravenous immunoglobulin resistance and coronary artery lesions in Kawasaki disease. World J Pediatr. 2019;15:168\u201375.","journal-title":"World J Pediatr"},{"key":"1211_CR48","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/1744-9987.12235","volume":"19","author":"Y Masuzawa","year":"2015","unstructured":"Masuzawa Y, Mori M, Hara T, Inaba A, Oba MS, Yokota S. Elevated D-dimer level is a risk factor for coronary artery lesions accompanying intravenous immunoglobulin-unresponsive Kawasaki disease. Ther Apher Dial. 2015;19:171\u20137.","journal-title":"Ther Apher Dial"},{"key":"1211_CR49","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1111\/pai.13495","volume":"32","author":"S Shao","year":"2021","unstructured":"Shao S, Yang L, Liu X, Liu L, Wu M, Deng Y, et al. Predictive value of coagulation profiles for both initial and repeated immunoglobulin resistance in Kawasaki disease: a prospective cohort study. Pediatr Allergy Immunol. 2021;32:1349\u201359.","journal-title":"Pediatr Allergy Immunol"},{"key":"1211_CR50","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S0140-6736(84)91504-6","volume":"2","author":"K Furusho","year":"1984","unstructured":"Furusho K, Kamiya T, Nakano H, Kiyosawa N, Shinomiya K, Hayashidera T, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet. 1984;2:1055\u20138.","journal-title":"Lancet"},{"key":"1211_CR51","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/S0022-3476(83)80300-X","volume":"102","author":"T Hidaka","year":"1983","unstructured":"Hidaka T, Nakano M, Ueta T, Komatsu Y, Yamamoto M. Increased synthesis of thromboxane A2 by platelets from patients with Kawasaki disease. J Pediatr. 1983;102:94\u20136.","journal-title":"J Pediatr"},{"key":"1211_CR52","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/0002-9149(88)91177-0","volume":"61","author":"DR Fulton","year":"1988","unstructured":"Fulton DR, Meissner C, Peterson MB. Effects of current therapy of Kawasaki disease on eicosanoid metabolism. Am J Cardiol. 1988;61:1323\u20137.","journal-title":"Am J Cardiol"},{"key":"1211_CR53","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1001\/jama.1985.03360060069027","volume":"254","author":"G Koren","year":"1985","unstructured":"Koren G, Rose V, Lavi S, Rowe R. Probable efficacy of high-dose salicylates in reducing coronary involvement in Kawasaki disease. JAMA. 1985;254:767\u20139.","journal-title":"JAMA"},{"issue":"Suppl 103","key":"1211_CR54","first-page":"209","volume":"35","author":"G Amarilyo","year":"2017","unstructured":"Amarilyo G, Koren Y, Brik SD, Bar-Meir M, Bahat H, Helou MH, et al. High-dose aspirin for Kawasaki disease: outdated myth or effective aid? Clin Exp Rheumatol. 2017;35(Suppl 103):209\u201312.","journal-title":"Clin Exp Rheumatol"},{"key":"1211_CR55","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2017-0098","author":"F Dallaire","year":"2017","unstructured":"Dallaire F, Fortier-Morissette Z, Blais S, Dhanrajani A, Basodan D, Renaud C, et al. Aspirin dose and prevention of coronary abnormalities in Kawasaki disease. Pediatrics. 2017;139","journal-title":"Pediatrics"},{"key":"1211_CR56","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1002\/acr.23504","volume":"70","author":"A Dhanrajani","year":"2018","unstructured":"Dhanrajani A, Chan M, Pau S, Ellsworth J, Petty R, Guzman J. Aspirin dose in Kawasaki disease: the ongoing battle. Arthritis Care Res. 2018;70:1536\u201340.","journal-title":"Arthritis Care Res"},{"key":"1211_CR57","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1542\/peds.96.6.1057","volume":"96","author":"K Durongpisitkul","year":"1995","unstructured":"Durongpisitkul K, Gururaj VJ, Park JM, Martin CF. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics. 1995;96:1057\u201361.","journal-title":"Pediatrics"},{"key":"1211_CR58","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/jpc.13816","volume":"54","author":"X Huang","year":"2018","unstructured":"Huang X, Huang P, Zhang L, Xie X, Xia S, Gong F, et al. Is aspirin necessary in the acute phase of Kawasaki disease? J Paediatr Child Health. 2018;54:661\u20134.","journal-title":"J Paediatr Child Health"},{"key":"1211_CR59","doi-asserted-by":"publisher","first-page":"725126","DOI":"10.3389\/fphar.2021.725126","volume":"12","author":"YH Huang","year":"2021","unstructured":"Huang YH, Hsin YC, Wang LJ, Feng WL, Guo MM, Chang LS, et al. Treatment of Kawasaki disease: a network meta-analysis of four dosage regimens of aspirin combined with recommended intravenous immunoglobulin. Front Pharmacol. 2021;12:725126.","journal-title":"Front Pharmacol"},{"key":"1211_CR60","doi-asserted-by":"publisher","DOI":"10.3390\/children7100185","author":"JE Kwon","year":"2020","unstructured":"Kwon JE, Roh DE, Kim YH. The impact of moderate-dose acetylsalicylic acid in the reduction of inflammatory cytokine and prevention of complication in acute phase of Kawasaki disease: the benefit of moderate-dose acetylsalicylic acid. Children (Basel). 2020;7","journal-title":"Children (Basel)"},{"key":"1211_CR61","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.3390\/clinpract14040105","volume":"14","author":"FM Safar","year":"2024","unstructured":"Safar FM, Kaabi WM, Aljudaibi RS, Alsaidi LM, Alharbi SS, Ibrahim AY, et al. The effectiveness of no or low-dose versus high-dose aspirin in treating acute Kawasaki Disease: a systematic review and meta-analysis. Clin Pract. 2024;14:1296\u2013309.","journal-title":"Clin Pract"},{"key":"1211_CR62","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1177\/000992280204100807","volume":"41","author":"FT Saulsbury","year":"2002","unstructured":"Saulsbury FT. Comparison of high-dose and low-dose aspirin plus intravenous immunoglobulin in the treatment of Kawasaki syndrome. Clin Pediatr Phila. 2002;41:597\u2013601.","journal-title":"Clin Pediatr Phila"},{"key":"1211_CR63","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/S0022-3476(97)70038-6","volume":"131","author":"M Terai","year":"1997","unstructured":"Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr. 1997;131:888\u201393.","journal-title":"J Pediatr"},{"key":"1211_CR64","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1016\/j.jacc.2015.12.073","volume":"67","author":"JW Newburger","year":"2016","unstructured":"Newburger JW, Takahashi M, Burns JC. Kawasaki disease. J Am Coll Cardiol. 2016;67:1738\u201349.","journal-title":"J Am Coll Cardiol"},{"key":"1211_CR65","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1007\/BF02072625","volume":"150","author":"T Akagi","year":"1991","unstructured":"Akagi T, Kato H, Inoue O, Sato N. Salicylate treatment in Kawasaki disease: high dose or low dose? Eur J Pediatr. 1991;150:642\u20136.","journal-title":"Eur J Pediatr"},{"key":"1211_CR66","doi-asserted-by":"publisher","first-page":"e689","DOI":"10.1542\/peds.2004-1037","volume":"114","author":"KS Hsieh","year":"2004","unstructured":"Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM. Treatment of acute Kawasaki disease: aspirin\u2019s role in the febrile stage revisited. Pediatrics. 2004;114:e689\u201393.","journal-title":"Pediatrics"},{"key":"1211_CR67","doi-asserted-by":"publisher","first-page":"e0144603","DOI":"10.1371\/journal.pone.0144603","volume":"10","author":"HC Kuo","year":"2015","unstructured":"Kuo HC, Lo MH, Hsieh KS, Guo MM, Huang YH. High-dose aspirin is associated with anemia and does not confer benefit to disease outcomes in Kawasaki disease. PLoS One. 2015;10:e0144603.","journal-title":"PLoS One"},{"key":"1211_CR68","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1161\/01.CIR.87.5.1776","volume":"87","author":"AS Dajani","year":"1993","unstructured":"Dajani AS, Taubert KA, Gerber MA, Shulman ST, Ferrieri P, Freed M, et al. Diagnosis and therapy of Kawasaki disease in children. Circulation. 1993;87:1776\u201380.","journal-title":"Circulation"},{"key":"1211_CR69","first-page":"401","volume":"250","author":"S Kusakawa","year":"1987","unstructured":"Kusakawa S, Tatara K. Efficacies and risks of aspirin in the treatment of the Kawasaki disease. Prog Clin Biol Res. 1987;250:401\u201313.","journal-title":"Prog Clin Biol Res"},{"key":"1211_CR70","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1136\/archdischild-2017-313538","volume":"102","author":"LGY Ho","year":"2017","unstructured":"Ho LGY, Curtis N. What dose of aspirin should be used in the initial treatment of Kawasaki disease? Arch Dis Child. 2017;102:1180\u20132.","journal-title":"Arch Dis Child"},{"key":"1211_CR71","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa003199","volume":"345","author":"F Catella-Lawson","year":"2001","unstructured":"Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345:1809\u201317.","journal-title":"N Engl J Med"},{"key":"1211_CR72","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/S0140-6736(81)91733-5","volume":"1","author":"SP Hanley","year":"1981","unstructured":"Hanley SP, Bevan J, Cockbill SR, Heptinstall S. Differential inhibition by low-dose aspirin of human venous prostacyclin synthesis and platelet thromboxane synthesis. Lancet. 1981;1:969\u201371.","journal-title":"Lancet"},{"key":"1211_CR73","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1002\/art.24660","volume":"60","author":"AC Lau","year":"2009","unstructured":"Lau AC, Duong TT, Ito S, Yeung RS. Intravenous immunoglobulin and salicylate differentially modulate pathogenic processes leading to vascular damage in a model of Kawasaki disease. Arthritis Rheum. 2009;60:2131\u201341.","journal-title":"Arthritis Rheum"},{"key":"1211_CR74","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1136\/archdischild-2019-318245","volume":"106","author":"MH Chiang","year":"2021","unstructured":"Chiang MH, Liu HE, Wang JL. Low-dose or no aspirin administration in acute-phase Kawasaki disease: a meta-analysis and systematic review. Arch Dis Child. 2021;106:662\u20138.","journal-title":"Arch Dis Child"},{"key":"1211_CR75","doi-asserted-by":"publisher","DOI":"10.1136\/bmjpo-2023-002312","author":"K Hayashi","year":"2024","unstructured":"Hayashi K, Miyakoshi C, Hoshino S, Kobayashi N, Nakajima R, Sagawa H, et al. Initial intravenous immunoglobulin therapy without aspirin for acute Kawasaki disease: a retrospective cohort study with a Bayesian inference. BMJ Paediatr Open. 2024;8","journal-title":"BMJ Paediatr Open"},{"key":"1211_CR76","doi-asserted-by":"publisher","first-page":"6303653","DOI":"10.1155\/2022\/6303653","volume":"2022","author":"K Liu","year":"2022","unstructured":"Liu K, Wang L, Gong L. High-dose or low-dose aspirin application in the initial phase of Kawasaki disease: a meta-analysis and systematic review. J Chem. 2022;2022:6303653.","journal-title":"J Chem"},{"key":"1211_CR77","doi-asserted-by":"publisher","first-page":"e0217274","DOI":"10.1371\/journal.pone.0217274","volume":"14","author":"X Zheng","year":"2019","unstructured":"Zheng X, Yue P, Liu L, Tang C, Ma F, Zhang Y, et al. Efficacy between low and high dose aspirin for the initial treatment of Kawasaki disease: current evidence based on a meta-analysis. PLoS One. 2019;14:e0217274.","journal-title":"PLoS One"},{"key":"1211_CR78","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1093\/rheumatology\/keaa050","volume":"59","author":"X Jia","year":"2020","unstructured":"Jia X, Du X, Bie S, Li X, Bao Y, Jiang M. What dose of aspirin should be used in the initial treatment of Kawasaki disease? A meta-analysis. Rheumatology (Oxford). 2020;59:1826\u201333.","journal-title":"Rheumatology (Oxford)"},{"key":"1211_CR79","doi-asserted-by":"crossref","unstructured":"Kuo HC, Lin MC, Kao CC, Weng KP, Ding Y, Chen CJ, et al. Efficacy of Intravenous Immunoglobulin alone on coronary artery lesion reduction in Kawasaki Disease. medRxiv. 2024.","DOI":"10.1101\/2024.07.11.24310310"},{"key":"1211_CR80","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ijcard.2016.06.062","volume":"220","author":"E Bachlava","year":"2016","unstructured":"Bachlava E, Loukopoulou S, Karanasios E, Chrousos G, Michos A. Management of coronary artery aneurysms using abciximab in children with Kawasaki disease. Int J Cardiol. 2016;220:65\u20139.","journal-title":"Int J Cardiol"},{"key":"1211_CR81","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/BF00798118","volume":"15","author":"T Kobayashi","year":"1994","unstructured":"Kobayashi T, Sone K. Effect of dipyridamole on the blood flow in coronary aneurysms resulting from Kawasaki disease. Pediatr Cardiol. 1994;15:263\u20137.","journal-title":"Pediatr Cardiol"},{"key":"1211_CR82","doi-asserted-by":"publisher","first-page":"18324","DOI":"10.1038\/s41598-023-45647-6","volume":"13","author":"L Gao","year":"2023","unstructured":"Gao L, Wang W, Wang H, Xu Z, Zhou S, Geng Z, et al. The safety and effectiveness of clopidogrel versus aspirin in Kawasaki disease with mild-to-moderate liver injury. Sci Rep. 2023;13:18324.","journal-title":"Sci Rep"},{"key":"1211_CR83","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s00246-007-9132-9","volume":"29","author":"Y Sugahara","year":"2008","unstructured":"Sugahara Y, Ishii M, Muta H, Iemura M, Matsuishi T, Kato H. Warfarin therapy for giant aneurysm prevents myocardial infarction in Kawasaki disease. Pediatr Cardiol. 2008;29:398\u2013401.","journal-title":"Pediatr Cardiol"},{"key":"1211_CR84","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1097\/MPH.0000000000002690","volume":"45","author":"N Montanez","year":"2023","unstructured":"Montanez N, Sexson Tejtel SK, Menon NM. Pediatric thromboprophylaxis of large coronary artery aneurysm using rivaroxaban. J Pediatr Hematol Oncol. 2023;45:356\u20139.","journal-title":"J Pediatr Hematol Oncol"},{"key":"1211_CR85","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1203\/01.PDR.0000061566.63383.F4","volume":"53","author":"H Senzaki","year":"2003","unstructured":"Senzaki H, Kobayashi T, Nagasaka H, Nakano H, Kyo S, Yokote Y, et al. Plasminogen activator inhibitor-1 in patients with Kawasaki disease: diagnostic value for the prediction of coronary artery lesion and implication for a new mode of therapy. Pediatr Res. 2003;53:983\u20138.","journal-title":"Pediatr Res"},{"key":"1211_CR86","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1177\/107602960100700306","volume":"7","author":"M Sakai","year":"2001","unstructured":"Sakai M, Asayama K, Otabe T, Kohri T, Shirahata A. Low tissue plasminogen activator relative to plasminogen activator inhibitor-1 as a marker of cardiac complication in children with Kawasaki disease. Clin Appl Thromb Hemost. 2001;7:214\u20138.","journal-title":"Clin Appl Thromb Hemost"},{"key":"1211_CR87","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1136\/hrt.78.5.517","volume":"78","author":"H Horigome","year":"1997","unstructured":"Horigome H, Sekijima T, Miyamoto T. Successful thrombolysis with intracoronary administration of tissue plasminogen activator in an infant with Kawasaki disease. Heart. 1997;78:517\u20138.","journal-title":"Heart"},{"key":"1211_CR88","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.1111\/ped.12130","volume":"55","author":"M Harada","year":"2013","unstructured":"Harada M, Akimoto K, Otaka M, Sato K, Oda H, Otsuki M, et al. Thrombolytic therapy in Kawasaki disease: a report of four cases. Pediatr Int. 2013;55:e111\u20135.","journal-title":"Pediatr Int"},{"key":"1211_CR89","doi-asserted-by":"publisher","first-page":"e1918565","DOI":"10.1001\/jamanetworkopen.2019.18565","volume":"3","author":"B Platt","year":"2020","unstructured":"Platt B, Belarski E, Manaloor J, Ofner S, Carroll AE, John CC, et al. Comparison of risk of recrudescent fever in children with Kawasaki disease treated with intravenous immunoglobulin and low-dose vs high-dose aspirin. JAMA Netw Open. 2020;3:e1918565.","journal-title":"JAMA Netw Open"},{"key":"1211_CR90","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12969-020-00432-x","volume":"18","author":"J Wang","year":"2020","unstructured":"Wang J, Chen H, Shi H, Zhang X, Shao Y, Hang B, et al. Effect of different doses of aspirin on the prognosis of Kawasaki disease. Pediatr Rheumatol Online J. 2020;18:48.","journal-title":"Pediatr Rheumatol Online J"},{"key":"1211_CR91","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00431-023-05302-8","volume":"183","author":"T Suzuki","year":"2024","unstructured":"Suzuki T, Michihata N, Hashimoto Y, Yoshikawa T, Saito K, Matsui H, et al. Association between aspirin dose and outcomes in patients with acute Kawasaki disease: a nationwide retrospective cohort study in Japan. Eur J Pediatr. 2024;183:415\u201324.","journal-title":"Eur J Pediatr"},{"key":"1211_CR92","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3389\/fped.2020.00249","volume":"8","author":"Y Ito","year":"2020","unstructured":"Ito Y, Matsui T, Abe K, Honda T, Yasukawa K, Takanashi JI, et al. Aspirin dose and treatment outcomes in Kawasaki disease: a historical control study in Japan. Front Pediatr. 2020;8:249.","journal-title":"Front Pediatr"},{"key":"1211_CR93","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2739\/kurumemedj.27.57","volume":"27","author":"T Yokoyama","year":"1980","unstructured":"Yokoyama T, Kato H, Ichinose E. Aspirin treatment and platelet function in Kawasaki disease. Kurume Med J. 1980;27:57\u201361.","journal-title":"Kurume Med J"},{"key":"1211_CR94","doi-asserted-by":"publisher","first-page":"146","DOI":"10.4103\/apc.APC_206_20","volume":"14","author":"F Sanati","year":"2021","unstructured":"Sanati F, Bagheri M, Eslami S, Khalooei A. Evaluation of high-dose aspirin elimination in the treatment of Kawasaki disease in the incidence of coronary artery aneurysm. Ann Pediatr Cardiol. 2021;14:146\u201351.","journal-title":"Ann Pediatr Cardiol"},{"key":"1211_CR95","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/pr.2018.44","volume":"83","author":"K Migally","year":"2018","unstructured":"Migally K, Braunlin EA, Zhang L, Binstadt BA. Duration of high-dose aspirin therapy does not affect long-term coronary artery outcomes in Kawasaki disease. Pediatr Res. 2018;83:1136\u201345.","journal-title":"Pediatr Res"},{"key":"1211_CR96","doi-asserted-by":"publisher","first-page":"182","DOI":"10.4070\/kcj.2013.43.3.182","volume":"43","author":"G Lee","year":"2013","unstructured":"Lee G, Lee SE, Hong YM, Sohn S. Is high-dose aspirin necessary in the acute phase of Kawasaki disease? Korean Circ J. 2013;43:182\u20136.","journal-title":"Korean Circ J"},{"key":"1211_CR97","first-page":"801","volume":"21","author":"YL Liu","year":"2019","unstructured":"Liu YL, Wang XM, Chen TT, Shi K, Lu YH, Guo YH, et al. Clinical effect and safety of clopidogrel combined with aspirin in antithrombotic therapy for children with Kawasaki disease complicated by small\/medium-sized coronary artery aneurysms. Zhongguo Dang Dai Er Ke Za Zhi. 2019;21:801\u20135.","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"key":"1211_CR98","doi-asserted-by":"publisher","first-page":"E4","DOI":"10.1542\/peds.109.1.e4","volume":"109","author":"RV Williams","year":"2002","unstructured":"Williams RV, Wilke VM, Tani LY, Minich LL. Does abciximab enhance regression of coronary aneurysms resulting from Kawasaki disease? Pediatrics. 2002;109:E4.","journal-title":"Pediatrics"},{"key":"1211_CR99","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/j.amjcard.2010.01.332","volume":"105","author":"RT McCandless","year":"2010","unstructured":"McCandless RT, Minich LL, Tani LY, Williams RV. Does abciximab promote coronary artery remodeling in patients with Kawasaki disease? Am J Cardiol. 2010;105:1625\u20138.","journal-title":"Am J Cardiol"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-026-01211-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11926-026-01211-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-026-01211-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:40:08Z","timestamp":1781631608000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11926-026-01211-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":99,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1211"],"URL":"https:\/\/doi.org\/10.1007\/s11926-026-01211-5","relation":{},"ISSN":["1534-6307"],"issn-type":[{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"31 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This paper does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}